8-K: Century Therapeutics Unveils T1D Program, Extends Cash Runway

Century Therapeutics announced its new iPSC-derived beta islet cell program for Type 1 diabetes, CNTY-813, alongside its Q3 2025 financial results and an extended cash runway into Q4 2027.

Summary

• A new Type 1 diabetes program, CNTY-813, an iPSC-derived beta islet cell therapy engineered with Allo-Evasion 5.0, has been announced.
• IND-enabling studies for CNTY-813 are expected to initiate by year-end 2025, with IND submission planned as early as 2026.
• CNTY-308, a CD19-targeted CAR-iT cell therapy, is advancing through IND-enabling studies, with clinical study initiation planned for 2026.
• CNTY-101 clinical development continues in the CARAMEL Phase 1/2 investigator-sponsored trial (IST) for B-cell-mediated autoimmune diseases, with initial clinical data expected in December 2025.
• The company is discontinuing its company-sponsored CALiPSO-1 trial for CNTY-101, which treated five patients with a favorable safety profile.
• Cash, cash equivalents, and marketable securities were $132.7 million as of September 30, 2025, compared to $220.1 million as of December 31, 2024.
• The estimated cash runway extends into the fourth quarter of 2027.
• Net loss for the three months ended September 30, 2025, was $34.4 million, compared to a net loss of $31.2 million for the same period in 2024.
• Research and Development (R&D) expenses decreased to $22.5 million for Q3 2025 from $27.2 million for Q3 2024.
• General and Administrative (G&A) expenses decreased to $6.8 million for Q3 2025 from $8.4 million for Q3 2024, primarily due to a $1.4 million gain on lease modification.
• Collaboration revenue for the nine months ended September 30, 2025, was $109.164 million, significantly up from $2.416 million for the same period in 2024.
• Net income for the nine months ended September 30, 2025, was $9.591 million, compared to a net loss of $90.493 million for the same period in 2024.
• An impairment of long-lived assets of $6.763 million was recorded for the three and nine months ended September 30, 2025.

Sentiment

Score: 7

Explanation: The filing presents a positive outlook with the introduction of a new, high-potential program for Type 1 Diabetes, strong preclinical data, and an extended cash runway. While there was a net loss for the quarter and a trial discontinuation, these are offset by strategic reprioritization, reduced expenses, and significant collaboration revenue for the nine-month period, indicating a focused and well-funded development path.

Positives

• Introduction of CNTY-813 for Type 1 Diabetes with compelling preclinical data demonstrating rapid and sustained glucose control without chronic immune suppression.
• Extension of the cash runway into the fourth quarter of 2027, providing financial stability for upcoming milestones.
• Advancement of CNTY-308 into IND-enabling studies with planned clinical initiation in 2026.
• Initial clinical data for CNTY-101 from the CARAMEL IST expected in December 2025.
• Significant increase in collaboration revenue and a shift to net income for the nine months ended September 30, 2025, compared to the prior year's net loss.
• Favorable safety profile observed in the discontinued CALiPSO-1 trial for CNTY-101, with encouraging clinical activity in refractory patient populations.
• Reduction in R&D and G&A expenses for Q3 2025 compared to Q3 2024.

Negatives

• Discontinuation of the company-sponsored CALiPSO-1 trial for CNTY-101, indicating a reprioritization of clinical development efforts.
• Net loss increased to $34.4 million in Q3 2025 from $31.2 million in Q3 2024.
• Cash, cash equivalents, and marketable securities decreased from $220.1 million at year-end 2024 to $132.7 million as of September 30, 2025.
• An impairment of long-lived assets of $6.763 million was recorded for the three and nine months ended September 30, 2025.

Risks

• Ability to successfully advance current and future product candidates through development activities, preclinical studies, and clinical trials.
• Ability to meet development milestones on anticipated timelines.
• Uncertainties inherent in the results of preliminary data, pre-clinical studies, and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials.
• Ability to obtain clearance of future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all.
• Reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of product candidates.
• Timing, scope, and likelihood of regulatory filings and approvals, including final regulatory approval of product candidates.
• Impact of geopolitical issues, trade disputes and tariffs, banking instability, and inflation on business and operations, supply chain, and labor force.
• Performance of third parties in connection with the development of product candidates, including third parties conducting clinical trials as well as third-party suppliers and manufacturers.
• Ability to successfully commercialize product candidates and develop sales and marketing capabilities, if product candidates are approved.
• Ability to recruit and maintain key members of management and ability to maintain and successfully enforce adequate intellectual property protection.

Future Outlook

Century Therapeutics anticipates initiating IND-enabling studies for CNTY-813 by year-end 2025, with a projected IND submission as early as 2026. Clinical studies for CNTY-308 are expected to commence in 2026. Initial clinical data from the CARAMEL IST for CNTY-101 is expected in December 2025. The company estimates its cash runway will support operations into the fourth quarter of 2027.

Management Comments

• "Today we announced our iPSC derived beta islet program for T1D. We have generated a compelling preclinical data package that underscores the tremendous opportunity to potentially deliver a functional cure for T1D. We are moving with urgency and anticipate initiating IND-enabling studies by the end of 2025, with a projected IND submission as early as 2026." Brent Pfeiffenberger, Pharm.D., Chief Executive Officer.
• "In parallel, we continue to advance CNTY-308 with plans to enter the clinic next year, supported by a strong and growing body of evidence from autologous CD19 CAR-T experience in autoimmune diseases." Brent Pfeiffenberger, Pharm.D., Chief Executive Officer.
• "Our priority remains on developing innovative therapies for high-impact areas. Consequently, we are focusing our resources and expertise on these two programs. With our iPSC Cell Foundry, Allo-Evasion 5.0 technology, and manufacturing know-how, we believe Century is uniquely positioned to deliver potentially curative cell therapies, and we are eager to advance our lead programs into the clinic as soon as possible." Brent Pfeiffenberger, Pharm.D., Chief Executive Officer.
• "With our cell foundry and Allo-Evasion 5.0 technology, we have engineered iPSC derived beta islets that we believe can deliver durable glycemic control without chronic immunosuppression." Chad Cowan, Ph.D., Chief Scientific Officer.
• "After initiating discovery activities earlier this year, we have now generated compelling preclinical data that underscores the deep potential of this program, including rapid and sustained normalization of glucose in diabetic mouse models, significant glucose-stimulated insulin secretion with detectable human C-peptide and engineered resistance to NK cell-mediated killing and antibody-dependent cellular cytotoxicity." Chad Cowan, Ph.D., Chief Scientific Officer.
• "Additionally, our suspension bioreactor process is capable of delivering mature, functional beta islets at scale, which we believe positions us to produce a consistent drug product suitable for broad patient access, if approved by regulatory authorities. Considering the large, underserved T1D patient population, we believe this program has great promise to be a potentially curative new therapy." Chad Cowan, Ph.D., Chief Scientific Officer.

Industry Context

The announcement of CNTY-813 for Type 1 Diabetes positions Century Therapeutics in a high-need area, leveraging advanced iPSC and immune evasion technologies. This aligns with a broader industry trend towards developing off-the-shelf cell therapies that overcome the limitations of autologous treatments (cost, manufacturing time) and allogeneic transplants (immune rejection, immunosuppression). The focus on autoimmune diseases with CAR-iT and CAR-iNK cells also reflects the growing interest in applying CAR-T/NK principles beyond oncology to address B-cell mediated autoimmune conditions, aiming for durable responses without chronic immunosuppression.

Comparison to Industry Standards

• CNTY-813 aims to provide glucose control without chronic immune suppression, addressing a major limitation of current allogeneic cadaveric islet transplantation, which often requires long-term immunosuppression with associated complications like reduced kidney function and melanoma.
• The company's iPSC-derived CAR-T cells (CNTY-308) are shown in preclinical studies to be functionally comparable to primary CAR-T cells, exhibiting similar IL-2 secretion, repeat killing capacity, persistence in blood, and tumor control after rechallenge. This suggests a potential for similar efficacy to established autologous CAR-T therapies but with the advantages of an off-the-shelf, scalable product.
• The Allo-Evasion 5.0 technology, incorporating HLA-I/II deletion, CD300a TASR ligand, and IgG degrading enzyme, aims to provide broader protection from host T cells, NK cells, and humoral immunity compared to earlier immune evasion strategies, potentially offering an advantage over other allogeneic cell therapy approaches.
• The observed rapid and effective depletion of circulating B-cells and the naive non-class switched profile of re-emergent B-cells with CNTY-101 in r/r NHL patients are consistent with responses seen in SLE patients treated with CD19-targeted cell therapies, suggesting a similar mechanism of action and potential for efficacy in autoimmune diseases.

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to a promising new program in a large market (T1D) and extended cash runway, but short-term volatility possible due to Q3 net loss and trial reprioritization.
• Patients (T1D): Hope for a potentially curative, off-the-shelf therapy that could eliminate the need for chronic immunosuppression and improve glucose control.
• Patients (Autoimmune): Continued development of CAR-iT and CAR-iNK therapies offers new treatment options, with initial data for CNTY-101 expected soon.
• Employees: Reprioritization of programs might lead to reallocation of resources, but overall focus on high-impact areas suggests stability for key development teams.
• Regulatory Authorities: Anticipated IND submissions for CNTY-813 and CNTY-308 will require thorough review of preclinical data and manufacturing processes.

Next Steps

• Initiate IND-enabling studies for CNTY-813 by year-end 2025.
• Submit an IND application for CNTY-813 as early as 2026.
• Initiate clinical studies for CNTY-308 in 2026.
• Present initial clinical data from the CARAMEL IST for CNTY-101 at the 14th Annual BMT & Cell Therapy Workshop on December 5, 2025.
• Continue patient enrollment in the CARAMEL Phase 1/2 IST for CNTY-101.

Key Dates

Recommendation

The announcement of a new, potentially transformative program for Type 1 Diabetes (CNTY-813) with strong preclinical data and an extended cash runway into Q4 2027 provides a significant positive catalyst for Century Therapeutics. The strategic reprioritization of CNTY-101 development, while involving the discontinuation of a company-sponsored trial, is offset by continued progress in an IST and a focus on higher-impact programs. The Q3 net loss is a concern, but the substantial collaboration revenue and net income for the nine-month period demonstrate underlying financial strength. Given the early stage of the new T1D program and the inherent risks in clinical development, a 'hold' recommendation is appropriate. Investors should monitor upcoming clinical data for CNTY-101 in December 2025 and the progress of IND-enabling studies for CNTY-813 and CNTY-308 for further indications of long-term potential. The company is making strategic moves to focus its pipeline, which is generally a positive, but the execution risk remains high for early-stage biotech.

Keywords

Century Therapeutics, iPSC, cell therapy, Type 1 Diabetes, T1D, CNTY-813, Allo-Evasion, autoimmune disease, CNTY-308, CNTY-101, CARAMEL IST, Q3 2025 earnings, biotechnology, CAR-T, CAR-NK, diabetes treatment, immune evasion, clinical trials, IND-enabling studies, financial results